Novo Holdings closes $16.5 billion buyout of contract manufacturer Catalent
Adds background throughout
Dec 18 (Reuters) -Novo Holdings, the controlling shareholder of Novo Nordisk NOVOb.CO, on Wednesday sealed its $16.5 billion deal for Catalent CTLT.N, as the Danish drugmaker looks to boost supplies of its widely popular weight-loss drug Wegovy.
Novo Nordisk will take control of three fill-finish facilities of the contract drug manufacturer in Italy, Belgium, and the U.S. as part of the deal. These sites will then be fully utilized by the company to fill its injection pens.
Novo Holdings agreed to buy Catalent in February, and several U.S. consumer groups and two large labor unions in October urged the Federal Trade Commission (FTC) to block the deal.
However, the FTC did not challenge the deal, and earlier this month European antitrust regulators also cleared the transaction after they found there were sufficient competing alternatives in the market.
Novo Nordisk launched Wegovy in the U.S. in 2021 and in 15 other countries since then.
The drug, chemically known as semaglutide, is part of a top-selling class of drugs designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow digestion and decrease appetite.
The soaring demand for these popular medicines has led to tight supply and companies, including Eli Lilly LLY.N, which makes the rival drug Zepbound, have been working to ramp up production.
Analysts estimate the obesity drug market could be worth as much as $150 billion globally per year in the next decade.
Novo Holdings and Catalent on Saturday disclosed that all regulatory conditions to close the deal were fulfilled.
Reporting by Bhanvi Satija and Mariam Sunny in Bengaluru; Editing by Maju Samuel and Sriraj kalluvila
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
